UCB (XBRU:UCB) Short-Term Capital Lease Obligation : €43 Mil (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is UCB Short-Term Capital Lease Obligation?

UCB's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €43 Mil.

UCB's quarterly Short-Term Capital Lease Obligation increased from Dec. 2022 (€40 Mil) to Jun. 2023 (€48 Mil) but then declined from Jun. 2023 (€48 Mil) to Dec. 2023 (€43 Mil).

UCB's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€38 Mil) to Dec. 2022 (€40 Mil) and increased from Dec. 2022 (€40 Mil) to Dec. 2023 (€43 Mil).

UCB Short-Term Capital Lease Obligation Historical Data

The historical data trend for UCB's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Short-Term Capital Lease Obligation Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

38.00

35.00

38.00

40.00

43.00

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															38.00	47.00	40.00	48.00	43.00

UCB Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

UCB Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of UCB's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (XBRU:UCB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (XBRU:UCB) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (XBRU:UCB) Headlines

No Headlines